-
公开(公告)号：WO2015076544A2
公开(公告)日：2015-05-28
申请号：PCT/KR2014/011050
申请日：2014-11-18
Applicant: 서울대학교산학협력단
IPC: A61B5/02 , A61B5/0452
CPC classification number: A61B5/02405 , A61B5/4848
-
公开(公告)号：KR1020140078384A
公开(公告)日：2014-06-25
申请号：KR1020120147677
申请日：2012-12-17
Applicant: 서울대학교산학협력단
IPC: A61K31/4515 , A61P35/00
CPC classification number: A61K31/4515 , A23L33/10 , A23V2002/00 , A23V2200/308
Abstract: The present invention relates to a pharmaceutical anti-cancer composition comprising haloperidol as an active ingredient, and provides a composition for treating or preventing cancer using haloperidol. Further, functional health food comprising the haloperidol is provided. The haloperidol according to the present invention facilitates the demethylation of DUSP6 genes and has anti-cancer effects by promoting the transcription of the DUSP6 genes. Reliability of the haloperidol is ensured since the haloperidol has been used as antipsychotic drugs for a long time, thereby the haloperidol can be easily developed as a cancer medicine.
Abstract translation: 本发明涉及包含氟哌啶醇作为活性成分的药物抗癌组合物，并提供使用氟哌啶醇治疗或预防癌症的组合物。 此外，提供了包含氟哌啶醇的功能保健食品。 根据本发明的氟哌啶醇促进DUSP6基因的去甲基化，并通过促进DUSP6基因的转录而具有抗癌作用。 氟哌啶醇的可靠性得到确保，因为氟哌啶醇已被长时间用作抗精神病药物，因此氟哌啶醇可以容易地作为癌症药物开发。
-
公开(公告)号：KR1020120038333A
公开(公告)日：2012-04-23
申请号：KR1020100100041
申请日：2010-10-13
Applicant: 서울대학교산학협력단
CPC classification number: C12Q1/6883 , C12Q1/6837 , C12Q2600/156
Abstract: PURPOSE: A polynucleotide for diagnosing bipolar disorders containing SNP is provided to early diagnose and to enable optimal treatment of the bipolar disorders. CONSTITUTION: A polynucleotide for diagnosing bipolar disorders contains or complementary polynucleotide thereof contains 10 or more serial bases having each 11th SNP in a polynucleotide of sequence number 1, 2, 3, or 4. A microarray for diagnosing bipolar disorders contains the polynucleotide, a polypeptide encoded by the polynucleotide, or cDNA thereof. A method for diagnosing the bipolar disorders comprises: a step of isolating nucleic acid sample containing a part of EGR2 gene from a test sample; and a step of determining the 11th base.
Abstract translation: 目的：提供用于诊断含有SNP的双相性精神障碍的多核苷酸，用于早期诊断并能够对双相性精神障碍进行最佳治疗。 构成：用于诊断双相性精神障碍的多核苷酸含有或互补的多核苷酸含有10个或更多个序列号1,2,3或4的多核苷酸中具有第11个SNP的连续碱基。用于诊断双相性精神障碍的微阵列含有多核苷酸，多肽 由多核苷酸编码，或其cDNA。 用于诊断双相性精神障碍的方法包括：从测试样品中分离含有一部分EGR2基因的核酸样品的步骤; 并确定第十一个基地的一个步骤。
-
公开(公告)号：KR1020150065962A
公开(公告)日：2015-06-16
申请号：KR1020130142583
申请日：2013-11-22
Applicant: 서울대학교산학협력단
IPC: A61B5/02 , A61B5/0452
CPC classification number: A61B5/02405 , A61B5/4848 , A61B5/02 , A61B5/0452
Abstract: 본원은피검자유래의심박변이도 (HRV)를제공하는단계; 및상기심박변이도를평균 RR(mean length of all RR intervals), SDNN (standard deviation of all RR interval), RMSSD (square root of the mean squared differences of successive normal sinus intervals), pNN20 (percentage of successive RR interval differences whose absolute value exceeded 20 ms), 파워스펙트럼밀도 (LF, HF 또는 LF/HF), ApEn (approximate entropy), SampEn (sample entropy), 알파및 CSE(corrected Shannon entropy)로구성되는군으로부터선택되는하나이상영역에서분석하는단계; 상기피검자의항정신병약물에대한주관적부작용검사결과를제공하는단계; 및상기분석결과를주관적부작용평가결과와연관시키는단계를포함하는, 항정신병약물에대한부작용평가방법을개시한다. 본원에따른방법은항정신병약물에대한치료반응또는치료순응과관련된부작용을예측할수 있어, 정신질환에대한보다효과적인약물치료를가능할수 있게한다.
Abstract translation: 公开了用于评估抗精神病药物诱导的副作用的方法，包括以下步骤：提供从受试者得到的心率变异性; 分析从平均RR（所有RR间期的平均长度），SDNN（所有RR间期的标准偏差），RMSSD（连续正常窦的均方差的平方根）组成的组中选择的一个或多个区域中的心率变异性 间隔），pNN20（绝对值超过20 ms的连续RR间期差的百分比），功率谱密度（LF，HF或LF / HF），ApEn（近似熵），SampEn（样本熵），Alpha和CSE（校正香农 熵）; 提供抗精神病药物对该受试者的副作用的主观评估结果; 并将分析结果与副作用的主观评估结果相结合。 根据本发明的方法能够使精神疾病的更有效的药物治疗作为与治疗反应相关的副作用或治疗对抗精神病药物的依从性的预测。
-
公开(公告)号：KR1020110069395A
公开(公告)日：2011-06-23
申请号：KR1020090126110
申请日：2009-12-17
Applicant: 서울대학교산학협력단
CPC classification number: C12Q1/6827 , C12Q1/6837
Abstract: PURPOSE: A SNP(single nucleotide polymorphism) of DUSP6 gene related to bipolar disorder is provided to screen a therapeutic agent for bipolar disorder. CONSTITUTION: A SNP(single nucleotide polymorphism) is a polynucleotide having 10 or more serial DNA sequence derived from DNA sequence of sequence number 1 containing 1524th base which is G; and a polynucleotide having 10 or more serial DNA sequence derived from the DNA sequence of sequence number 1 containing 2683th base which is C; or a complementary polynucleotide thereof. A probe for diagnosing bipolar disorder contains the polynucleotide. A microarray for diagnosing bipolar disorder contains the probe. A kit for diagnosing bipolar disorder contains the polynuelcotide. A method for diagnosing bipolar disorder comprises: a step of preparing a nucleic acid sample from a test sample; and a step of determining nucleotide sequence of SNP.
Abstract translation: 目的：提供与双相障碍相关的DUSP6基因的SNP（单核苷酸多态性）筛选双相型精神障碍的治疗剂。 构成：SNP（单核苷酸多态性）是具有来源于序列号1的DNA序列的10个以上的连续DNA序列的多核苷酸，其含有第1524位碱基，为G; 以及衍生自序列号1的DNA序列的10个以上的连续DNA序列的多核苷酸，其含有第2683位碱基，为C; 或其互补多核苷酸。 用于诊断双相障碍的探针含有多核苷酸。 用于诊断双相障碍的微阵列包含探针。 用于诊断双相障碍的试剂盒含有多核苷酸。 诊断双相障碍的方法包括：从测试样品制备核酸样品的步骤; 以及确定SNP的核苷酸序列的步骤。
-
Patent Agency Ranking
公开(公告)号：KR1020130005915A
公开(公告)日：2013-01-16
申请号：KR1020110067606
申请日：2011-07-08
Applicant: 서울대학교산학협력단
IPC: A61N1/36 , A61B5/0476 , A61B5/0482 , A61N1/08
CPC classification number: A61N1/36 , A61B5/0476 , A61B5/0482 , A61N1/08
Abstract: PURPOSE: A spasm end-point decision method using sample entropy of brain wave is provided to rapidly measure the end-point of spasm. CONSTITUTION: A spasm end-point decision method using sample entropy of brain wave comprises the following steps: obtaining brain wave change data according to time from experimentee; using starting time point information of the section after partitioning the brainwave data according to the time of 1-20 seconds; measuring the sample entropy value about the divided each section; selecting N number of sections by selecting the section having the lowest sample entropy value in order; reversely, calculating the absolute mean value of the brain wave amplitude up to 5-20 seconds before; distinguishing the status convulsivus and ratio status convulsivus; and determining the starting point of the last section as the spasm end-point.
Abstract translation: 目的：提供使用脑波样本熵的痉挛终点决策方法，快速测量痉挛的终点。 构成：使用脑波样本熵的痉挛终点决策方法包括以下步骤：根据实验者的时间获取脑波变化数据; 根据1-20秒的时间划分脑波数据后，使用该部分的开始时间点信息; 测量关于分割的每个部分的样本熵值; 通过选择具有最低样本熵值的部分来选择N个部分; 相反，计算脑波幅度的绝对平均值高达5-20秒; 区分痉挛状态和比例状态惊厥; 并将最后一节的起点确定为痉挛终点。
-
公开(公告)号：KR101070122B1
公开(公告)日：2011-10-05
申请号：KR1020090107243
申请日：2009-11-06
Applicant: 서울대학교산학협력단
IPC: A61B5/02 , A61B5/0452 , A61B5/046
Abstract: 본발명은정신분열병환자들의심박변이도(heart rate variability, HRV)를측정하여정신분열병을진단하는장치및 방법에관한것이다. 보다구체적으로본 발명은 HRV의여러측정지표가정신분열병환자에서특징적인변화를보이는것을제시한다. HRV의측정지표중에서도 SampEn (sample entropy)은 HRV의복잡성을나타나는지표이며, LF/HF (ration of low frequency to high frequency)는 HRV에서교감신경계와부교감신경계가서로균형을이루는정도를나타낸다. SampEn과 LF/HF 측정값을이용하여정신분열병환자를특이적으로진단할수 있으며, 정신분열병치료제의스크리닝및 효능평가에이용할수 있다.
-
公开(公告)号：KR1020110050315A
公开(公告)日：2011-05-13
申请号：KR1020090107243
申请日：2009-11-06
Applicant: 서울대학교산학협력단
IPC: A61B5/02 , A61B5/0452 , A61B5/046
Abstract: PURPOSE: A device and method for diagnosing schizophrenia using a heart rate variability measurement factor are provided to simply verify a medicine of schizophrenia. CONSTITUTION: A device and method for diagnosing schizophrenia(100) comprises a heart rate variability measurement unit(110), a database unit(120), and a processing unit(130). The heart rate variability measurement unit measure the heart rate variability of a subject. The database unit stores a diagnostic criteria of SampEn(sample entorpy) and LF/HF(low frequency/high frequency) through a clinical trials of a schizophrenic under predetermined conditions The processing unit calculates SampEn(sample entorpy) and LF/HF(low frequency/high frequency) using the measured data from the heart rate variability measurement unit and compares it with the diagnostic criteria.
Abstract translation: 目的：提供使用心率变异性测量因子诊断精神分裂症的装置和方法，以简单地验证精神分裂症药物。 构成：用于诊断精神分裂症的装置和方法（100）包括心率变异性测量单元（110），数据库单元（120）和处理单元（130）。 心率变异性测量单元测量受试者的心率变异性。 数据库单元通过预定条件下的精神分裂症临床试验存储SampEn（样本熵）和LF / HF（低频/高频）的诊断标准。处理单元计算SampEn（样本熵）和LF / HF（低频 /高频），使用来自心率变异性测量单元的测量数据并将其与诊断标准进行比较。
-
公开(公告)号：KR101262526B1
公开(公告)日：2013-05-08
申请号：KR1020110067606
申请日：2011-07-08
Applicant: 서울대학교산학협력단
IPC: A61N1/36 , A61B5/0476 , A61B5/0482 , A61N1/08
Abstract: 본발명은뇌파의표본엔트로피를이용한경련종료시점결정방법및 경련종료시점분석장치를제공하는데있다. 본발명은전기경련치료에있어서경련의종료시점을정확하고신속하게측정할수 있는장점을가진다. 또한, 본발명에따른경련종료시점및 지속시간측정방법은전기경련치료시행의치료효과를보다신뢰성있게예측하는데 이용될수 있을뿐 만아니라간질등 다른질환의뇌파검사에서도본 방법을이용하여발작의발생및 종료여부등에대한정보를제공할수 있다.
-
公开(公告)号：KR101249635B1
公开(公告)日：2013-04-01
申请号：KR1020100100041
申请日：2010-10-13
Applicant: 서울대학교산학협력단
Abstract: 본 발명은 SNP를 포함하는 양극성 장애 진단용 폴리뉴클레오타이드와 이를 이용한 마이크로어레이 및 키트에 관한 것이다. 또한, 본 발명은 SNP를 이용한 양극성 장애 진단방법에 관한 것이다. 본 발명의 SNP를 이용한 진단방법은 양극성 장애의 발병 및 그 확률을 조기에 진단하여 양극성 장애 치료에 필요한 최적의 치료를 제공할 수 있으며, 유전자 지문 분석과 같은 양극성 장애와 관련된 용도로 사용할 수 있다. 또한, 본 발명의 양극성 장애와 관련된 SNP를 분석하면 양극성 장애의 위험도에 대한 기초적 정보를 제공할 수 있다.
-
-
-
-
-
-
-
-
-
Search Results
11
records
(took 0.021 seconds)
